Table 1.

Demographic and clinicopathologic characteristics of the surgery and RFA groups

Characteristics	Surgery group (n = 150)	RFA group (n = 151)	p value
Patient factors
Age, median (IQR), years	68 (63–74)	69 (63–74)	0.85
Sex, male:female	112:38	108:43	0.54
Performance status, n (%)
0	147 (98)	146 (97)
1	3 (2)	4 (3)	0.56
2	0	1 (1)
Child-Pugh score, n (%)
5	117 (78)	129 (85)
6	22 (15)	20 (13)	0.07
7	10 (7)	2 (1)
Hepatitis C virus infection, n (%)	97 (65)	94 (62)	0.66
Hepatitis B virus infection,* n (%)	27 (18)	33 (22)	0.42
Use of antiviral therapy, n (%)	23 (15)	21 (14)	0.58
Serum albumin level, median (IQR), g/dL	4.0 (3.7–4.3)	4.1 (3.7–4.4)	0.48
Total bilirubin level, median (IQR), mg/dL	0.7 (0.5–1.0)	0.8 (0.6–1.0)	0.58
Prothrombin time, median (IQR), %	91 (81–99)	94 (86–100)	0.01
Platelet count, median (IQR), 104/µL	13.0 (9.9–16.8)	13.5 (9.8–17.5)	0.62
Creatinine level, median (IQR), mg/dL	0.7 (0.6–0.9)	0.7 (0.6–0.9)	0.73
Absence of ascites,* †n (%)	145 (97)	149 (99)	0.16
History of other cancers,* n (%)	13 (9)	7 (5)	0.23
Comorbidity, ischemic heart disease, n (%)	2 (1)	2 (1)	0.61
Pretreatment TACE*	11 (7)	12 (8)	0.59
HCC clinical factors
HCCs, n	1 (1–1)	1 (1–1)	0.97
≥2, n (%)	15 (10)	15 (10)	0.98
Largest HCC diameter, median (IQR), cm	1.8 (1.5–2.2)	1.8 (1.5–2.3)	0.89
≤2.0 cm, n (%)	98 (65)	101 (67)	0.78
HCC histopathologic factors, n (%)
HCC	131 (87)	30 (20)	−
Well-differentiated	39 (26)	10 (7)
Moderately differentiated	85 (57)	16 (11)
Poorly differentiated	7 (5)	4 (3)
Unknown	19 (13)	121 (80)

* Data missing on hepatitis B virus infection for 1 patient, the absence of ascites for 1 patient, history of other cancers for 1 patient, comorbidity of ischemic heart disease for 1 patient, and pretreatment TACE for 1 patient. ^†Including patients treated with diuretics.